{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:32:14Z","timestamp":1773779534195,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Autologous stem cell transplantation (ASCT) remains a cornerstone in the management of multiple myeloma (MM). However, the optimal timing of ASCT and the factors determining whether patients ultimately undergo transplantation remain unclear in real-world practice. The Revised Myeloma Comorbidity Index (R-MCI) was developed to quantify patient fitness but its influence on transplant eligibility and timing has not been fully characterized. Methods: We conducted a retrospective single-center study including 137 patients with newly diagnosed MM between 2015 and 2025. Clinical parameters recorded at diagnosis included age, sex, performance status, renal and pulmonary function, cytogenetic risk, International Staging System (ISS) stage, and bone marrow plasma cell infiltration. The R-MCI was calculated for all patients. Transplant timing was categorized as early (\u226412 months) or delayed (&gt;12 months) after diagnosis. Logistic regression analysis was performed, and variables with p &lt; 0.10 in univariate analyses were included in the multivariate model. Early versus delayed ASCT was defined as \u226412 months or &gt;12 months from diagnosis, respectively. Results: ASCT was performed in 61\/137 patients (44.5%), while 42.6% of these underwent early transplantation. Transplanted patients were significantly younger (&lt;65 years: 82.0% vs. 25.0%, p &lt; 0.001) and had lower R-MCI scores (median 0 vs. 1, p &lt; 0.001) compared with non-transplanted patients, while plasma cell infiltration and ISS stage did not differ. In multivariate analysis, R-MCI was the only variable showing a trend toward predicting early transplantation (OR 0.27, 95% CI 0.07\u20131.06, p = 0.06). Conclusions: In real-world MM management, patients quantified by R-MCI appear to play a more prominent role than disease burden in determining both eligibility for and timing of ASCT. Incorporating comorbidity indices alongside ISS may enhance individualized transplant decision-making and optimize treatment outcomes.<\/jats:p>","DOI":"10.3390\/diagnostics15233038","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:31:46Z","timestamp":1764689506000},"page":"3038","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Determinants of Eligibility and Timing of Autologous Transplantation in Multiple Myeloma: The Role of R-MCI and Diagnostic Plasma Cell Burden"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4288-6370","authenticated-orcid":false,"given":"Ozlem","family":"Candan","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-3809","authenticated-orcid":false,"given":"Arda","family":"Bayar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narmin","family":"Naghizada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-8759","authenticated-orcid":false,"given":"Derya","family":"Demirtas","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-0149","authenticated-orcid":false,"given":"Ahmet Mert","family":"Yanik","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asu Fergun","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Tulin","family":"Tuglular","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-8581","authenticated-orcid":false,"given":"Tayfur","family":"Toptas","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isik","family":"Atagunduz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Marmara University School of Medicine, Pendik Training and Research Hospital, 34899 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-024-01115-6","article-title":"A roadmap towards improving outcomes in multiple myeloma","volume":"14","author":"Mohty","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/hemato5040030","article-title":"Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma","volume":"5","author":"Blackburn","year":"2024","journal-title":"Hemato"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/j.clml.2021.04.006","article-title":"Disparities in utilization of autologous stem cell transplantation as consolidative therapy for multiple myeloma: A single institution retrospective review","volume":"21","author":"Lupak","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","article-title":"Increased bone marrow plasma-cell percentage predicts outcomes in newly diagnosed multiple myeloma patients","volume":"20","author":"Parmar","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jtct.2023.08.028","article-title":"Overcoming barriers to autologous stem cell transplantation in multiple myeloma: Recommendations from a multidisciplinary roundtable discussion","volume":"29","author":"Bashir","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41409-024-02227-0","article-title":"Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: Impact of ASCT, transplant refusal and high-risk MM","volume":"59","author":"Tang","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1016\/j.clml.2022.04.020","article-title":"Multiple myeloma: Impact of time to transplant on the outcome","volume":"22","author":"Kumar","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13597","article-title":"Comorbidities in multiple myeloma and implications on survival: A population-based study","volume":"106","author":"Thorsteinsdottir","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_16","first-page":"4519","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: A systematic review and meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1038\/bcj.2017.14","article-title":"Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma","volume":"7","author":"Lee","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2019-127030","article-title":"The Revised Myeloma Comorbidity Index (R-MCI) as a promising approach for predicting overall (os)-and progression-free (pfs) survival and optimizing therapy strategies in multiple myeloma (mm) patients (pts)-comparative analysis of 5 comorbidity indices (ci), including retro-and prospective applicability","volume":"134","author":"Schoeller","year":"2019","journal-title":"Blood"},{"key":"ref_20","first-page":"593","article-title":"Optimizing individualized therapy decision-making in multiple myeloma (MM): Integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board","volume":"104","author":"Dreyling","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12288-015-0575-5","article-title":"Multiple myeloma: Treatment is getting individualized","volume":"32","author":"Agarwal","year":"2016","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_22","first-page":"660","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","article-title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"8","author":"Ebraheem","year":"2024","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2018-99-116014","article-title":"Depth of response and outcomes in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"760.e1","DOI":"10.1016\/j.jtct.2022.07.030","article-title":"Deepening responses after upfront autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in the era of novel agent induction therapy","volume":"28","author":"Ebraheem","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1111\/bjh.17391","article-title":"Using depth of response to stratify patients to front line autologous stem cell transplant: Results of the phase II PADIMAC myeloma trial","volume":"193","author":"Popat","year":"2021","journal-title":"Br. J. Haematol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/23\/3038\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:46:37Z","timestamp":1764690397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/23\/3038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":27,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["diagnostics15233038"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15233038","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}